Validation of Progranulin as a Biomarker for Sepsis

NCT03280576 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 556

Last updated 2019-08-15

No results posted yet for this study

Summary

Progranulin blood concentrations in patients with sepsis will be analysed in relation to disease status in order to validate progranulin as a biomarker for sepsis. Patients undergoing cardiac surgery will serve as controls.

Conditions

Sponsors & Collaborators

  • City of Munich

    collaborator OTHER_GOV
  • Ludwig-Maximilians - University of Munich

    lead OTHER

Principal Investigators

  • Gustav Schelling, M.D. · Department of Anaesthesiology LMU

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2019-04-30
Completion
2019-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03280576 on ClinicalTrials.gov